Welcome to our dedicated page for TriSalus Life Sciences SEC filings (Ticker: TLSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The TriSalus Life Sciences, Inc. (Nasdaq: TLSI) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports on Form 8-K and other key documents filed with the U.S. Securities and Exchange Commission. TriSalus identifies itself in these filings as an emerging growth company and an oncology-focused medical technology business built around its Pressure-Enabled Drug Delivery (PEDD) platform and investigational immunotherapy, nelitolimod.
Through Forms 8-K, TriSalus reports material events such as quarterly financial results, business updates, changes in directors, compensation decisions and capital structure actions. Recent 8-K filings describe press releases announcing results for quarters ended June 30 and September 30, 2025, along with revenue performance driven by sales of the TriNav system. Other 8-Ks detail an exchange offer and consent solicitation related to Series A Convertible Preferred Stock, amendments to the certificate of designations, and subsequent conversion of preferred shares into common stock.
These filings also document governance and compensation matters, including director resignations and adjustments to executive base salary and performance-based stock option grants that vest upon achieving specified revenue thresholds. Together, they provide insight into how TriSalus manages its capital structure, aligns management incentives and responds to financing needs while advancing its PEDD-based devices and clinical-stage immunotherapy.
On Stock Titan, SEC documents for TLSI are updated as they are made available through EDGAR. AI-powered tools can help summarize lengthy filings, highlight key sections related to revenue, operating results, capital structure changes and governance items, and make it easier to interpret the implications of each report. This allows users to quickly understand what TriSalus is disclosing about its operations, financial condition and strategic decisions without reading every page in detail.
TriSalus Life Sciences reported a performance-based grant of 248,899 employee stock options to the reporting person, exercisable at $5.11. The options become exercisable immediately if the company achieves $75 million of revenue in any consecutive 12-month period ending on or before December 31, 2027, and vesting is subject to the holder's continued service on each vesting date. If the revenue threshold is not met, the options expire on December 31, 2027. Following this reported grant, the reporting person beneficially owns 538,899 shares of common stock.
Utmost Group PLC reports beneficial ownership of 2,000,588 shares of TriSalus Life Sciences Inc. common stock, representing 0.0529% of the outstanding class. The filing states Utmost has sole voting and dispositive power over all reported shares and identifies Lombard International Assurance SA as a subsidiary acquired by Utmost on 30/12/2024. The disclosure explains the percentage ownership fell because TriSalus’ total outstanding shares increased to 37,838,962. The filing is a Schedule 13G indicating passive reporting under the Exchange Act rules and includes Utmost’s UK address and an authorized signature by the Group CFO dated 08/11/2025.
TriSalus Life Sciences insider award summary: Chief Financial Officer David Patience received equity awards on 08/14/2025 consisting of 200,000 restricted stock units (RSUs) payable in common stock and an employee stock option to purchase 290,000 shares at an exercise price of $3.88 per share. Following these grants, the reporting person beneficially owns 200,000 common shares and 290,000 option shares directly. The RSUs vest in four equal annual installments beginning July 1, 2026, subject to continued service. The option vests 25% on the one-year anniversary of the July 1, 2026 vesting commencement date, with the remainder vesting monthly thereafter until fully vested, and expires on 08/13/2035.
TriSalus Life Sciences received a Schedule 13G reporting that Nantahala Capital Management, LLC and its managing members, Wilmot B. Harkey and Daniel Mack, each may be deemed the beneficial owner of 2,000,000 shares of TriSalus common stock, representing 5.29% of the class as of June 30, 2025. The filing states the shares are held by funds and separately managed accounts under Nantahala's control, and the reported position reflects shared voting and dispositive power only, with no sole voting or sole dispositive authority. The Reporting Persons certify the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
TriSalus Life Sciences reported accelerating product revenue and improved liquidity but continues to record operating losses and faces substantial doubt about its ability to continue as a going concern. Revenue for Q2 2025 rose to $11.213 million from $7.364 million a year earlier, producing gross profit of $9.411 million for the quarter and $17.083 million for the six months ended June 30, 2025, compared with $11.938 million a year earlier. Cash and cash equivalents increased to $26.8 million at June 30, 2025 from $8.5 million at year-end 2024, driven primarily by a $22.0 million private placement and draws under the OrbiMed Credit Agreement.
The company reported a six-month net loss available to common stockholders of $18.663 million and an accumulated deficit of $298.2 million. Total assets were $41.3 million versus total liabilities of $60.7 million, producing a stockholders' deficit of $19.4 million. Management disclosed substantial doubt about near-term liquidity and expects to require additional capital through collaborations, equity or debt to fund operations.
FAQ
What is the current stock price of TriSalus Life Sciences (TLSI)?
What is the market cap of TriSalus Life Sciences (TLSI)?
